Your browser doesn't support javascript.
loading
A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells.
Kegler, Alexandra; Drewitz, Laura; Arndt, Claudia; Daglar, Cansu; Rodrigues Loureiro, Liliana; Mitwasi, Nicola; Neuber, Christin; González Soto, Karla Elizabeth; Bartsch, Tabea; Baraban, Larysa; Ziehr, Holger; Heine, Markus; Nieter, Annabel; Moreira-Soto, Andres; Kühne, Arne; Drexler, Jan Felix; Seliger, Barbara; Laube, Markus; Máthé, Domokos; Pályi, Bernadett; Hajdrik, Polett; Forgách, László; Kis, Zoltán; Szigeti, Krisztián; Bergmann, Ralf; Feldmann, Anja; Bachmann, Michael.
Afiliación
  • Kegler A; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
  • Drewitz L; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
  • Arndt C; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
  • Daglar C; Mildred Scheel Early Career Center, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Rodrigues Loureiro L; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
  • Mitwasi N; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
  • Neuber C; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
  • González Soto KE; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
  • Bartsch T; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
  • Baraban L; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
  • Ziehr H; Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
  • Heine M; Department of Pharmaceutical Biotechnology, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Braunschweig, Germany.
  • Nieter A; Department of Pharmaceutical Biotechnology, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Braunschweig, Germany.
  • Moreira-Soto A; Department of Pharmaceutical Biotechnology, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Braunschweig, Germany.
  • Kühne A; Institute of Virology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Drexler JF; Institute of Virology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Seliger B; Institute of Virology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  • Laube M; Medical Faculty, Martin-Luther-University Halle-Wittenberg, Halle, Germany.
  • Máthé D; Institute of Translational Immunology, Medical High School, Brandenburg an der Havel, Germany.
  • Pályi B; Department of Radiopharmaceutical and Chemical Biology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
  • Hajdrik P; Department of Biophysics and Radiation Biology, Faculty of Medicine, Semmelweis University, Budapest, Hungary.
  • Forgách L; Hungarian Centre of Excellence for Molecular Medicine, In Vivo Imaging Advanced Core Facility, Szeged, Hungary.
  • Kis Z; CROmed Translational Research Ltd., Budapest, Hungary.
  • Szigeti K; National Biosafety Laboratory, Division of Microbiological Reference Laboratories, National Public Health Center, Budapest, Hungary.
  • Bergmann R; Department of Biophysics and Radiation Biology, Faculty of Medicine, Semmelweis University, Budapest, Hungary.
  • Feldmann A; Semmelweis University School of Pharmacy, Semmelweis University, Budapest, Hungary.
  • Bachmann M; National Biosafety Laboratory, Division of Microbiological Reference Laboratories, National Public Health Center, Budapest, Hungary.
Front Immunol ; 14: 1204543, 2023.
Article en En | MEDLINE | ID: mdl-37383226
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Límite: Animals / Humans Idioma: En Revista: Front Immunol Año: 2023 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Límite: Animals / Humans Idioma: En Revista: Front Immunol Año: 2023 Tipo del documento: Article País de afiliación: Alemania